GlobeNewswire

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex

Share

– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe –

– TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3

LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older. This approval, which represents the third indication for GW’s cannabidiol in Europe, paves the way for the expanded launch of the medicine across Europe.

“This is an exciting moment for patients, and their families, who are affected by this debilitating disease and may benefit from this treatment. This approval is the result of the continued dedication of GW and the physician and patient communities to address this serious unmet medical need,” said Justin Gover, GW’s Chief Executive Officer. “We now look forward to working with each European member state to make EPIDYOLEX® available to appropriate patients across Europe, as quickly as possible.”

Dr. Volker Knappertz, GW’s Chief Medical Officer, said, “We are excited by the news of this approval by the European Commission and the benefits EPIDYOLEX could bring to the community. The clinical data supporting EPIDYOLEX in TSC provides hope of a better quality of life for patients. This medicine provides more choice for physicians managing seizures associated with TSC and has the potential to benefit the thousands of patients who do not respond to the current standard of care.”

Professor Alexis Arzimanoglou, Coordinator of the European Reference Network for Rare and Complex Epilepsies ERN EpiCARE (University Hospitals of Lyon, France), added, “Those suffering from TSC and those involved in their care will welcome this European approval. Given the demonstrated efficacy and safety profile of EPIDYOLEX, this important development could offer a much-needed treatment option to those most in need.”

The approval is based on data from a positive Phase 3 safety and efficacy study evaluating 25 mg/kg/day of GW’s cannabidiol. The study met its primary endpoint, which was the reduction in seizure frequency compared to baseline of cannabidiol vs placebo, with seizure reduction of 49% in patients taking cannabidiol 25 mg/kg/day compared with 27% for placebo (p=0.0009). All key secondary endpoints were supportive of the effects on the primary endpoint. The safety profile observed was consistent with findings from previous studies, with no new safety risks identified.

TSC is a condition that causes mostly benign tumours to grow in vital organs of the body, including the brain, skin, heart, eyes, kidneys and lungs, and in which epilepsy is the most common neurological feature. TSC is typically diagnosed in childhood.4

GW’s cannabidiol was originally approved by the European Medicines Agency (EMA) in September 2019 under the tradename EPIDYOLEX® as an adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

The EC decision is valid in all 27 countries of the European Union, alongside Norway, Iceland and Liechtenstein.

ADDITIONAL INFORMATION

About GW Pharmaceuticals plc
GW Pharmaceuticals (GW), and U.S. subsidiary Greenwich Biosciences, is a UK-based global biopharmaceutical company that has established a world-leading position in cannabinoid science and medicine. Founded over two decades ago in response to significant unmet patient need, patients remain our key focus and improving their quality of life, our motivation. GW’s pioneering work has led to the regulatory approval of world first, potentially life improving, cannabis-based medicines. Our continued dedication has resulted in the treatment of thousands of patients with our medicines around the world. For further information, please visit www.gwpharm.co.uk

About EPIDIOLEX®/EPIDYOLEX® (cannabidiol)
EPIDIOLEX®/EPIDYOLEX® (cannabidiol), the first prescription, plant-derived cannabis-based medicine approved by the U.S. Food and Drug Administration (FDA) for use in the U.S. and the European Commission (EC) for use in Europe, is an oral solution which contains highly purified cannabidiol (CBD). In the U.S., EPIDIOLEX® is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome or Tuberous Sclerosis Complex (TSC) in patients one year of age and older. EPIDIOLEX® has received approval in the European Union under the tradename EPIDYOLEX® for adjunctive use in conjunction with clobazam to treat seizures associated with LGS and Dravet syndrome in patients two years and older, and for adjunctive use to treat seizures associated with TSC, in patients two years of age and older. EPIDYOLEX® has received Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment of seizures associated LGS, Dravet syndrome, and Tuberous Sclerosis Complex (TSC).

About Tuberous Sclerosis Complex (TSC)
Tuberous Sclerosis Complex (TSC) is a rare genetic condition that has an estimated prevalence in the EU of 10 in 100,000.5 The condition causes mostly benign tumours to grow in vital organs of the body including the brain, skin, heart, eyes, kidneys and lungs and is a leading cause of genetic epilepsy.4,5 The onset of epilepsy in TSC often occurs in the first year of life with patients initially suffering from predominantly focal seizures or infantile spasms. It is associated with an increased risk of autism and intellectual disability.1 The severity of the condition can vary widely. In some children the disease is very mild, while others may experience life-threatening complications.6,7

Enquiries
All investor and media enquiriespublicrelations@gwpharm.com
GW Pharmaceuticals plc
Scott Giacobello, Chief Financial Officer+1 760 795 2200
UK, EU and ex-U.S. media enquiries
FTI Consulting
Michael Trace / Ben Atwell+44 (0)203 727 1000
U.S. media enquiries
Kristen Cardillo, Corporate Communications+1 760 579 6628
  1. Nabbout R, Belousova E, Benedik MP, et al. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. Epilepsia Open. 2019 Mar; 4(1): 73–84.
  2. 2 Boston Children’s Hospital. https://www.childrenshospital.org/conditions-and-treatments/conditions/t/tuberous-sclerosis-tsc/symptoms-and-causes. Accessed March 2021.
  3. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010;51(7):1236–41.
  4. NIH Tuberous Sclerosis Fact Sheet. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Tuberous-Sclerosis-Fact-Sheet.
  5. Prevalence and incidence of rare diseases: Bibliographic data. https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf
  6. TS Alliance Website. https://www.tsalliance.org/. Accessed March 2021
  7. de Vries PJ, Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis. 2018;13(1):157.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Mandalay Resources Provides Target Release Date for First Quarter 2021 Financial Results and Conference Call10.5.2021 23:00:00 CEST | Press release

TORONTO, May 10, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (“Mandalay” or “the Company”) (TSX: MND, OTCQB: MNDJF) announces that its first quarter 2021 financial results will be released after market close on May 12, 2021, followed by a conference call with Dominic Duffy, President and Chief Executive Officer of Mandalay, for investors and analysts on May 13, 2021, at 8:00 AM (Toronto time). Analysts and interested investors are invited to participate using the following dial-in numbers: Participant Number:(201) 689-8341Participant Number (Toll free):(877) 407-8289Conference ID:13719805 A replay of the conference call will be available until 11:59 PM (Toronto time), May 27, 2021, and can be accessed using the following dial-in number: Encore Toll Free Dial-in Number:(877) 660-6853Encore ID:13719805 For Further Information: Dominic Duffy President and Chief Executive Officer Edison Nguyen Manager, Analytics and Investor Relations Contact: (647) 260-1566 About Mandalay Reso

Industrivärden divests its shareholding in SSAB for SEK 2,019 million10.5.2021 23:00:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Industrivärden has today divested its entire holding of 44,334,933 class A shares in SSAB at a price of SEK 45.53 per class A share, corresponding to a total proceeds of SEK 2,019 million. The divestment has been made by means of an accelerated book building process addressed to institutional investors. The divested shares represent 4.3 percent of the capital and 11.8 percent of the votes in SSAB. Commenting on the transaction, Industrivärden’s CEO Helena Stjernholm says: “Industrivärden has been a long-term and committed owner with a significant shareholding in SSAB since 1994. Within the framework of our ownership role, we have actively participated in several important development steps, s

Industrivärden avyttrar sitt aktieinnehav i SSAB för 2.019 mnkr10.5.2021 23:00:00 CEST | Pressemelding

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER SPRIDNING, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, JAPAN ELLER SYDAFRIKA ELLER ANNAN JURISDIKTION DÄR SÅDAN DISTRIBUTION ELLER PUBLICERING SKULLE VARA OLAGLIG. SE AVSNITTET VIKTIG INFORMATION I SLUTET AV DETTA PRESSMEDDELANDE. Industrivärden har idag avyttrat hela sitt aktieinnehav i SSAB om 44 334 933 A-aktier för 45,53 kronor per A-aktie, motsvarande en total försäljningslikvid om 2.019 mnkr. Avyttringen har skett genom en så kallad accelererad bookbuilding-process riktad till institutionella investerare. De avyttrade aktierna motsvarar 4,3 procent av kapitalet och 11,8 procent av röstetalet i SSAB. I en kommentar till försäljningen säger Industrivärdens vd, Helena Stjernholm: ”Industrivärden har varit en långsiktig och engagerad ägare med ett betydande aktieinnehav i SSAB sedan 1994. Inom ramen för vår ägarroll har vi aktivt deltagit i flera viktiga utvecklingssteg, såsom till exempel inriktningen mot produktområden med

CrossAmerica Partners LP Reports First Quarter 2021 Results10.5.2021 22:15:00 CEST | Press release

Allentown, PA, May 10, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Reports First Quarter 2021 Results Reported First Quarter 2021 Operating Loss of $0.9 million and Net Loss of $4.0 million compared to Operating Income of $77.4 million and Net Income of $72.1 million for the First Quarter 2020. During the First Quarter 2020, CrossAmerica recorded a gain on sale totaling $70.9 million, primarily driven by the sale of its 17.5% investment in CST Fuel SupplyGenerated First Quarter 2021 Adjusted EBITDA of $20.7 million and Distributable Cash Flow of $15.8 million compared to First Quarter 2020 Adjusted EBITDA of $25.3 million and Distributable Cash Flow of $20.4 millionReported First Quarter 2021 Gross Profit for the Wholesale Segment of $34.9 million compared to $35.1 million of Gross Profit for the First Quarter 2020Distributed 291.8 million wholesale fuel gallons during the First Quarter 2021 at an average wholesale fuel margin per gallon of 7.3 cents compared to 220.6 million who

The largest shareholder of JSC Olainfarm continues to maintain stake in the company10.5.2021 20:34:00 CEST | Press release

JSC Olainfarm has received information from the company Black Duck Invest a.s. registered in the Czech Republic that it has an intention to acquire the shares of JSC Olainfarm owned by Olmafarm Ltd., which makes up 42.56% of the shares of JSC Olainfarm. JSC Olainfarm has not received information that the transaction has taken place. According to the public information, Olmafarm Ltd. has approached the State Police and an investigation has been started. JSC Olainfarm has not been informed about changes in the register of shareholders in connection with the shares of JSC Olainfarm owned by Olmafarm Ltd. The Management Board of JSC Olainfarm actively monitors the situation and will continue to provide information in accordance with the legal requirements. JSC Olainfarm, a part of Olainfarm Group, is one of the leading pharmaceutical companies in the Baltic States offering high quality medicine and chemical pharmaceutical products. The business strategy “FORWARD” highlights the company’s m

Nokia selected by Movistar Chile for commercial 5G network launch10.5.2021 20:00:00 CEST | Press release

Press Release Nokia selected by Movistar Chilefor commercial 5G network launch Movistar Chile’s commercial 5G network to launch with Nokia’s AirScale technology The deal upgrades Telefónica’s 4G and 4G+ network across several Chilean cities; option for a seamless upgrade to 5G services in the future This high-speed mobile technology will be supported by Movistar Chile's fiber optics, which will allow the different mobile antennas deployed in cities to be interconnected May 10, 2021 Espoo, Finland – Nokia has today announced that it has been chosen by Telefónica’s Latin America brand, Movistar Chileto provide equipment from its AirScale portfolio to launch the operator’s 5G network in the country. This milestone deployment will enable 5G services for Movistar customers. In addition, Nokia will upgrade Movistar’s 4G and 4G+ networks to strengthen the critical network backbone across Chile’s key markets. To meet the demands from consumers and businesses for improved speeds and enhanced se

Bel : First quarter 2021 financial information : Sales10.5.2021 18:00:00 CEST | Press release

Suresnes — May 10, 2021 at 6 p.m. Bel First quarter 2021 financial information Sales Organic sales growth up slightly after adjusting for Covid impact in 2020 Q1 2021 sales totaled €840.2 million1, down 7.5% on a published basis. Sales declined 3.6%(2) organically, but grew 0.2% after excluding the Q1 2020 sales spike tied to the Covid-19 pandemic. Amounts are expressed in millions of euros and rounded off to the nearest million. Ratios and variances are calculated based on underlying amounts, not rounded off amounts. Antoine Fievet, Chairman and Chief Executive Office of the Bel Group, said, "I want to thank all of Bel's employees, who mobilized once again this quarter to fight the Covid-19 pandemic and its consequences on our activities and their personal lives. The unprecedented growth that we reported in Q1 2020, buoyed by increased food purchases and stockpiling by consumers around the world, automatically led to a sales decline at the beginning of this year. While our business en